Business
HLS Therapeutics Announces $43,500,000 Million Bought Deal Offering
HLS Therapeutics Announces $43,500,000 Million Bought Deal Offering Canada NewsWir...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics Announces $43,500,000 Million Bought Deal Offering\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nETOBICOKE, ON, May 14, 2019\n\n\n\n/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./\n ETOBICOKE, ON, May 14, 2019 /CNW/ -  HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX:HLS) today announced that it has entered into a bought deal agreement with GMP Securities L.P. and Bloom Burton Securities Inc. (together, the \"Lead Underwriters\"), pursuant to which the Lead Underwriters have agreed to purchase 2,718,750 common shares of the Company (the \"Common Shares\") at a price of $16.00 per Common Share (the \"Issue Price\") for gross proceeds of $43,500,000 (the \"Offering\"). In addition, the underwriters of the Offering will have the option, exercisable until 30 days after the closing date, to acquire up to an aggregate of 407,813 additional Common Shares at the Issue Price to cover over-allotments, if any (the \"Over-Allotment Option\"). If the Over-Allotment Option is exercised in full, the total gross proceeds of the Offering will be $50,025,008.\nThe Common Shares will be offered by way of a short form prospectus to be filed in in each of the provinces of Canada, except Quebec, and in the United States by way of private placement pursuant to the exemption from registration provided for under Rule 144A of the United States Securities Act of 1933, as amended, and in such other jurisdictions outside of Canada and the United States as are agreed to by the Company and the Lead Underwriters, in each case provided that no prospectus, registration statement or other similar document is required to be filed in such jurisdiction and that the Company will not be or become subject to any continuous disclosure obligations in such jurisdiction. The Offering is scheduled to close on or about June 5, 2019 and the net proceeds of the Offering will be used for business development activities to support the...